Free Newsletter
SPOTLIGHT: Novartis: No more deals, no Roche sale
Free newsletter via e-mail
Tools
Two questions raised by yesterday's Novartis-Alcon announcement. Is the Swiss drug maker in the market for more deals? And might Novartis offload its one-third stake in Roche to pay for Alcon or some other acquisition. CEO Daniel Vasella (photo) answers both: No. Report | Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: